Thermo Fisher Scientific Inc. (NYSE:TMO) – Stock analysts at Leerink Swann reduced their Q1 2019 EPS estimates for Thermo Fisher Scientific in a research note issued on Wednesday, January 30th, according to Zacks Investment Research. Leerink Swann analyst P. Souda now anticipates that the medical research company will post earnings per share of $2.76 for the quarter, down from their previous forecast of $2.77. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q2 2019 earnings at $2.95 EPS, Q3 2019 earnings at $2.96 EPS, Q4 2019 earnings at $3.45 EPS, FY2019 earnings at $12.13 EPS, Q1 2020 earnings at $3.07 EPS, Q2 2020 earnings at $3.33 EPS, Q3 2020 earnings at $3.32 EPS, Q4 2020 earnings at $3.78 EPS and FY2020 earnings at $13.50 EPS.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research note on Monday, November 19th. BTIG Research raised their price objective on Thermo Fisher Scientific to $290.00 and gave the company a “buy” rating in a research note on Thursday, January 31st. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $275.10.
Shares of NYSE TMO opened at $243.51 on Monday. Thermo Fisher Scientific has a fifty-two week low of $194.51 and a fifty-two week high of $253.91. The company has a quick ratio of 1.23, a current ratio of 1.71 and a debt-to-equity ratio of 0.64. The company has a market cap of $98.03 billion, a price-to-earnings ratio of 21.90, a price-to-earnings-growth ratio of 1.60 and a beta of 1.14.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 30th. The medical research company reported $3.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.19 by $0.06. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.26 billion. During the same quarter last year, the firm earned $2.79 earnings per share. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. K.J. Harrison & Partners Inc bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $3,661,000. Oakworth Capital Inc. lifted its holdings in shares of Thermo Fisher Scientific by 30.0% in the 3rd quarter. Oakworth Capital Inc. now owns 1,476 shares of the medical research company’s stock worth $360,000 after purchasing an additional 341 shares during the last quarter. XR Securities LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $375,000. Blue Chip Wealth Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 26.5% in the 3rd quarter. Blue Chip Wealth Management Inc. now owns 2,154 shares of the medical research company’s stock worth $526,000 after purchasing an additional 451 shares during the last quarter. Finally, WealthPLAN Partners LLC raised its stake in Thermo Fisher Scientific by 8.3% during the 3rd quarter. WealthPLAN Partners LLC now owns 2,488 shares of the medical research company’s stock valued at $581,000 after acquiring an additional 190 shares in the last quarter. 86.88% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Gregory J. Herrema sold 17,235 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $247.00, for a total value of $4,257,045.00. Following the completion of the transaction, the insider now owns 26,446 shares in the company, valued at approximately $6,532,162. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Tyler Jacks sold 4,772 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $239.75, for a total value of $1,144,087.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,607 shares of company stock valued at $7,972,085. Insiders own 0.49% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.